Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Randomized controlled trial of an oral gastrin receptor antagonist for the treatment of postmenopausal osteoporosis

Title: Randomized controlled trial of an oral gastrin receptor antagonist for the treatment of postmenopausal osteoporosis
Authors: Schini, Marian; Gossiel, Fatma; Paggiosi, Margaret A; Hilditch, Sara L; More, Stuart; Modlin, Irvin; Eastell, Richard
Contributors: Clifton Life Biosciences LLC
Source: Journal of Bone and Mineral Research ; volume 41, issue 4, page 387-395 ; ISSN 0884-0431 1523-4681
Publisher Information: Oxford University Press (OUP)
Publication Year: 2025
Description: High gastrin levels may help to explain the association between several conditions and osteoporosis, such as pernicious anemia, the use of proton pump inhibitors, and atrophic gastritis. This study aimed to determine whether administering a gastrin receptor antagonist (GRA) to older women would lower their bone turnover markers (BTM) and, therefore, be a suitable preventive measure for osteoporosis. We conducted a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy, safety, and tolerability of an oral GRA (netazepide) 100 mg administered daily for 90 d in postmenopausal women. Our primary endpoint was the change in the BTM plasma CTX (automated immunoassay analyzer) at days 0, 7, 28, 56, and 90. We also measured other BTMs, and gastrin and group I pepsinogens (ELISA assays). We studied the effect of the drug on the log-transformed baseline scaled ratio for BTM and gastric markers using mixed-model ANOVA for the fixed effects of treatment, time, and the treatment-by-time interaction, with the baseline value included as a covariate. We studied 99 women, with a mean age of 60 yr and bone mineral density (BMD) T-scores for the spine and total hip (TH) of −0.96 and −0.09, respectively. We found that gastrin increased by 90% in response to GRA as early as 7 d (p-value for treatment: .0008), and group I pepsinogens decreased by 15% as early as 7 d (p-value: .0002). There was no significant change in plasma CTX. A high percentage of women (81/99) completed the study, and the GRA was well tolerated. Gastrin receptor antagonist had the expected effects on the gastric markers with an increase in gastrin and a decrease in group I pepsinogens. However, the absence of any change in the bone resorption marker plasma CTX was a bit surprising. Based on this study, it appears that short-term gastrin receptor antagonism is unlikely to be a successful strategy in the prevention of osteoporosis. However, this is a preliminary exploration of a novel hypothesis and larger studies might be needed.
Document Type: article in journal/newspaper
Language: English
DOI: 10.1093/jbmr/zjaf165
DOI: 10.1093/jbmr/zjaf165/65246204/zjaf165.pdf
Availability: https://doi.org/10.1093/jbmr/zjaf165; https://academic.oup.com/jbmr/advance-article-pdf/doi/10.1093/jbmr/zjaf165/65246204/zjaf165.pdf; https://academic.oup.com/jbmr/article-pdf/41/4/387/65246204/zjaf165.pdf
Rights: https://creativecommons.org/licenses/by/4.0/
Accession Number: edsbas.875E2DDB
Database: BASE